Bradykinin Receptor Antagonist Compounds for Pain Relief
Summary
The USPTO published patent application US20260108535A1 on April 23, 2026, covering bradykinin receptor antagonist compounds for therapeutic use. The application (No. 19423236, filed December 17, 2025) specifies pharmaceutical compositions for treatment of urinary bladder pain and symptomatic relief of pain, burning, urgency, and frequency arising from lower urinary tract mucosa irritation caused by infection, trauma, surgery, endoscopic procedures, or catheter passage. The named inventors include Pathik Subhashchandra Brahmkshatriya, Vishal Bharatbhai Unadkat, Vishalgiri Gunvantgiri Goswami, Heta Nishil Pandya, and Sandip Pareshbhai Mehta.
“The present invention relates to compounds useful as bradykinin receptor antagonist, pharmaceutical composition comprising such compounds, and therapeutic use of the same.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published a patent application for bradykinin receptor antagonist compounds classified under CPC A61K 31/655. The compounds are directed toward therapeutic use in treating urinary bladder pain and providing symptomatic relief from pain, burning, urgency, and frequency associated with lower urinary tract mucosa irritation from infection, trauma, surgery, endoscopic procedures, or catheter passage.
Affected parties in the pharmaceutical sector should note this publication as potential prior art for overlapping compound patents and therapeutic indications. Generic drug manufacturers and research institutions working on bradykinin receptor antagonists or urological pain treatments may need to review this application during freedom-to-operate analyses.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOUNDS USEFUL TO TREAT PAIN
Application US20260108535A1 Kind: A1 Apr 23, 2026
Inventors
Pathik Subhashchandra Brahmkshatriya, Vishal Bharatbhai Unadkat, Vishalgiri Gunvantgiri Goswami, Heta Nishil Pandya, Sandip Pareshbhai Mehta
Abstract
The present invention relates to compounds useful as bradykinin receptor antagonist, pharmaceutical composition comprising such compounds, and therapeutic use of the same. The present invention further relates to the combination of compounds useful for the therapeutic use. The present invention relates to the pharmaceutical composition comprising the compound and combination of compounds useful for treatment of urinary bladder pain, the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.
CPC Classifications
A61K 31/655
Filing Date
2025-12-17
Application No.
19423236
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.